Union européenne -
français -
EMA (European Medicines Agency)
opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - mélanome - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.
Suisse -
français -
Swissmedic (Swiss Agency for Therapeutic Products)
opdualag (80 mg relatlimab / 240 mg nivolumab pro 20 ml) solution à diluer pour perfusion
bristol-myers squibb sa - relatlimabum, nivolumabum - solution à diluer pour perfusion - relatlimabum 80 mg, nivolumabum 240 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, acidum penteticum, aqua ad iniectabile ad solutionem pro 20 ml. - fortgeschrittenes melanom - biotechnologika